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Abstract
Background: The use of tolerogenic DCs is a promising therapeutic strategy for transplantation and autoimmune
disorders. Immunomodulatory DCs are primarily generated from monocytes (MDDCs) for in vitro experiments
following protocols that fail to fulfil the strict regulatory rules of clinically applicable products. Here, we compared
the efficacy of three different tolerance-inducing agents, dexamethasone, rapamycin and vitamin D3, on DC
biology using GMP (Good Manufacturing Practice) or clinical grade reagents with the aim of defining their use for
human cell therapy.
Methods: Tolerogenic MDDCs were generated by adding tolerogenic agents prior to the induction of maturation
using TNF-a, IL-b and PGE2. We evaluated the effects of each agent on viability, efficiency of differentiation,
phenotype, cytokine secretion and stability, the stimulatory capacity of tol-DCs and the T-cell profiles induced.
Results: Differences relevant to therapeutic applicability were observed with the cellular products that were
obtained. VitD3-induced tol-DCs exhibited a slightly reduced viability and yield compared to Dexa-and Rapa-tol-
DCs. Phenotypically, while Dexa-and VitD3-tol-DCs were similar to immature DCs, Rapa-tol-DCs were not
distinguishable from mature DCs. In addition, only Dexa-and moderately VitD3-tol-DCs exhibited IL-10 production.
Interestingly, in all cases, the cytokine secretion profiles of tol-DCs were not modified by a subsequent TLR
stimulation with LPS, indicating that all products had stable phenotypes. Functionally, clearly reduced alloantigen T
cell proliferation was induced by tol-DCs obtained using any of these agent. Also, total interferon-gamma (IFN-g)
secretion by T cells stimulated with allogeneic tol-DCs was reduced in all three cases, but only T cells co-cultured
with Rapa-tol-DCs showed impaired intracellular IFN-g production. In addition, Rapa-DCs promoted CD4+ CD127
low/negative CD25high and Foxp3+ T cells.
Conclusions: Our results demonstrate contrasting influences of different clinical-grade pharmacological agents on
human tol-DC generation. This should be taken into account for decisions on the use of a specific agent for the
appropriate cellular therapy in the context of a particular disease.
Background
Autoimmune diseases are characterized by the loss of
tolerance toward self-antigens and the induction of
destructive immune responses leading to tissue damage.
Most patients with autoimmune diseases are treated
with immunosuppressive drugs that induce a generalized
immune suppression, which increases the risk of infec-
tious diseases and cancer [1]. Thus, induction of toler-
ance is an important goal for treating autoimmune
disorders or to prevent undesirable immune responses
against allogeneic transplants [2-8].
Research in recent years has primarily focused on
developing more selective immunosuppressive or immu-
nomodulatory therapies with fewer side effects and with
the potential for long-term disease remission. In this
context, the use of antigen-specific tolerogenic dendritic
cells (tol-DCs) that target autoreactive T cells is an
attractive strategy, with the aim of reprogramming the
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ders [9-11].
Dendritic cells (DCs) are professional antigen-present-
ing cells that have the potential to either stimulate or
inhibit immune responses [12-15]. Their broad range of
powerful immune stimulatory and regulatory functions
has placed DCs at centre stage of active immunotherapy
[16-23]. Dendritic cells maintain immune tolerance to
self-antigens by deleting or controlling the pathogenicity
of autoreactive T-cells. Modifications of DCs in the
laboratory can enhance and stabilise their tolerogenic
properties, and several pharmacological agents, such as
dexamethasone (Dexa), rapamycin (Rapa) and vitamin
D3 (VitD3), may promote the tolerogenic activities of
DCs [24,25]. It has been widely reported that such
maturation-resistant DCs can regulate autoreactive or
alloreactive T-cell responses and promote or restore
antigen-specific tolerance in experimental animal models
[26-36].
Yet, the current challenge is to move tol-DCs from the
bench to the bedside [37-41], and one of the major tasks
is to translate laboratory protocols into clinically-applic-
able procedures. Currently, information on different tol-
erogenic cellular products can be found at the research
level. Therefore, a systematic comparison of the required
functional characteristics of the various clinical tolero-
genic DCs is necessary.
In this study, we compared the effects of three immu-
nomodulatory agents: Dexa, Rapa and VitD3, on tol-
DCs generation using clinical grade reagents. We
describe both the convenient and inconvenient aspects
of each different “tolerogenic cellular products” to
induce tolerance and discuss the eligibility of each cellu-
lar product for particular therapeutic scenarios.
Methods
Culture Media and reagents
Culture medium used was X-VIVO 15 (BioWhittaker
®,
Lonza, Belgium) supplemented with 2% (vol/vol) heat-
inactivated AB human serum (BioWhittaker
®,L o n z a ,
Belgium), 2 mM L-glutamine (Sigma-Aldrich Company
LTD, Saint Louis, MO, USA), 100 U/mL penicillin
(Cepa S.L, Madrid, Spain), and 100 μg/mL streptomycin
(Laboratorios Normon S.A, Madrid, Spain).
Monoclonal Antibodies
The following murine mAbs were used. FITC-labelled
mAbs: CD86 and Foxp3 (BD Biosciences, CA, USA);
PE-labelled mAbs: CD14 (ImmunoTools GmbH, Ger-
many), CD40 and CD127 (BD Biosciences); PerCP-
labelled mAb: CD3 (BD Biosciences); PE-Cyanine dye 5-
labelled mAb: CD25 (BD Biosciences); PE-Cyanine dye
7-labelled mAb: CD14 (BD Biosciences); Allophycocya-
nin (APC)-labelled mAbs: CD83, CD4 and anti-IFN-g
(BD Biosciences); APC-H7-labelled mAb: HLA-DR (BD
Biosciences).
Immunostaining and flow cytometry
Cells were washed, resuspended in 50 μlo fP B Sa n d
incubated with mAbs for 15-18 minutes at room tem-
perature (RT). After washing, acquisition used a Facs-
Canto II flow cytometer with Standard FacsDiva
software (BD Biosciences). Subsequent analyses used
FlowJo software (Tree Star, Inc, OR, USA). Samples
w e r eg a t e du s i n gf o r w a r d( F S C )a n ds i d e( S S C )s c a t t e r
to exclude dead cells and debris.
Cell Isolation
Buffy coats, provided by our Blood Bank department,
were obtained from healthy blood donors following the
institutional Standard Operating Procedures for blood
donation and processing. Peripheral Blood Mononuclear
Cells (PBMCs) were isolated by Ficoll-Paque (Lympho-
prep, Axis Shield, Oslo, Norway) density gradient centri-
fugation at 400 × g for 25 min. Recovered cells were
washed twice in PBS and counted using Perfect Count
microspheres (Cytognos SL, Salamanca, Spain) following
the manufacturer’s instructions. The Ethical Committee
of Germans Trias i Pujol Hospital approved the study,
and all subjects gave their informed consent according
to the Declaration of Helsinki (BMJ 1991; 302: 1994).
Establishing Monocyte-derived DCs
PBMCs were depleted of CD3+ T cells using a Rosette-
Sep™ Human CD3 Depletion Cocktail (StemCell Tech-
nologies, Seattle, WA, USA). Monocytes were obtained
by positive selection using an EasySep
® Human CD14
Positive Selection Kit (StemCell Technologies, Seattle,
WA, USA). For all samples, the purity and viability of
the monocyte populations were greater than 95% and
90% respectively, as assessed by the expression of speci-
fic markers and Annexin V + and 7-Amino-actinomycin
D (7AAD) labelling (BD Biosciences).
Monocytes were cultured at 1-1.1 ×10
6/ml for 6 days
in cGMP-grade XVIVO15 containing penicillin (100 U/
ml) and streptomycin (100 μg/ml) in the presence of
clinical-grade granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF: 1000 U/ml; CellGenix, Freiburg,
Germany) and interleukin 4 (IL-4: 1000 U/ml; Cell-
Genix, Freiburg, Germany). Cells were replenished on
d a y2w i t hah a l fv o l u m eo ff r e s hm e d i u ma n dc y t o -
kines, and complete fresh medium and cytokines on day
4. To induce mature DCs (Mat-DCs), DCs were treated
with a cGMP-grade cytokines cocktail: TNF-a (1000 U/
mL) and IL-b (10 ng/mL) (both from CellGenix); and
PGE2 (1 μM) (Pfizer, New York, USA) on day 4. Tol-
DCs were established by treatment with either Dexa (1
μM, Fortecortín, Merck Farma y Química, S.L, Spain),
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days 2 and 4, or VitD3 (1 nM, Calcijex, Abbott) on days
0 and 4. Tol-DCs were stimulated as mature DCs at day
4 with the cytokine cocktail. On day 6, DCs were har-
vested and washed extensively twice before functional
assays were performed.
Allostimulatory assays
PBMCs were labelled with CFSE and plated (10
5 cells/
well) in 96-well round-bottom plates. Mononuclear cells
were co-cultured for 6 days with MDDCs at a 1:20 ratio
(DC: PBMC). Cell proliferation was determined by the
sequential loss of CFSE fluorescence of CD3 positive
cells, as detected by flow cytometry.
Intracellular cytokine staining
Mononuclear cells isolated from healthy donors were
seeded in 96-well round bottom plates (Nunc) at a den-
sity of 1 × 10
5 cells/well and stimulated for 6 days with
allogeneic DCs (5 × 10
3 DC/well). Then, total cells were
stimulated with 50 ng/mL phorbol 12-myristate 13-acet-
ate (PMA, Sigma) plus 500 ng/mL ionomycin (Sigma)
for 5 h in the presence of 10 μg/ml brefeldin A (Sigma).
After stimulation, cells were washed with PBS and
stained for 18 min at RT with PerCP-conjugated anti-
human CD3 mAb (BD Biosciences). Cells were then
washed, fixed and permeabilised using an IntraStain kit
(Dako) and incubated for 28 min at RT with anti-
human IFNg APC mAb (eBioscience). Cells were washed
and analysed with a BD-FACScanto II flow cytometer
equipped with FACSDiva software (Becton-Dickinson).
Measurements of cytokine production
Interleukin 10 (IL-10), IL-12p70 and IL-23 were deter-
mined in supernatants of activated DCs using MILLI-
PLEX Multi-Analyte Profiling (MAP; Millipore
Corporate Headquarters, MA, USA) following the man-
ufacturer’s instructions. These supernatants were col-
lected after 48 h upon maturation and also after strong
TLR (LPS: 100 ng/mL from E. Coli 0111:B4, Sigma.
Reference: L4391) re-stimulation for 24 h and analysed
for the presence of the indicated cytokines.
Supernatants from allogeneic co-cultures were col-
lected after 6 days, stored at -20°C, and analyzed by
MILLIPLEX Multi-Analyte Profiling (IL-10) and ELISA
(TGFb, eBioscience).
Determination of CD4+ CD127 low/negative CD25high
and Foxp3+ T cells
CD3+ T lymphocytes were purified from mononuclear
cells by negative selection using an EasySep
® Human T
Cell Enrichment Kit (StemCell Technologies) following
the manufacturer’s instructions. Purity was > 95% in all
experiments. Enriched T cells were plated (10
5 cells/
well) in 96-well round-bottom plates. After 6 days of
co-culture (1DC:20T), we used flow cytometry to deter-
mine the percentages of Tregs defined as CD4+,
CD127
low/negative,C D 2 5
high and intracellular Foxp3+, as
previously reported [42] (Human Regulatory T Cell
Staining Kit; eBioscience, San Diego, CA, USA).
Statistical analyses
R e s u l t sa r eg i v e na sm e a n s±s t a n d a r dd e v i a t i o n s( S D )
f o rns a m p l e sp e rg r o u p .R e s u l t sa r et h em e a n so fa t
least 5 replicates for each experiment. Comparisons
used either parametric paired t-tests or non-parametric
Wilcoxon tests, as appropriate. A p-value ≤ 0.05 was
considered statistically significant. Prism software
(GraphPad v4.00 software. CA, USA) was used for sta-
tistical analysis.
Results
Dexa, Rapa and VitD3 generate tol-DCs under GMP
conditions
Most clinical studies use MDDCs to obtain adequate
numbers of cells to warrant clinical doses for patients.
We first evaluated the viabilities and yields of the differ-
entiation processes using parallel conditions for the
same individual for each of 5 different donors. In order
to establish a common, objective baseline for compara-
tive purposes, dose-dependent experiments were set up
to obtain the optimal concentration of each immunomo-
dulatory agent that induced an arbitrary 50% reduction
of allostimulatory capacity compared to mature DCs
(similar to immature DCs) with high viability (≥ 85%
viable cells) (additional file 1:, Figure S1). Rapa-and
VitD3-tol-DCs exhibited 50-70% reductions of T prolif-
eration at 10 nM and 1 nM, respectively, while Dexa
required a concentration 100-1000 times higher (1 μM)
to achieve similar results. These criteria allowed us to
evaluate equivalent tolerogenic products using the fol-
lowing final concentrations: 1 μMD e x a ,1 0n MR a p a
and 1 nM VitD3.
Simultaneous staining of cells with PE-annexin V and
with the non-vital dye 7AAD was used to discriminate
viable cells (Figure 1A). These results showed that, com-
pared to mature DCs, only VitD3 treatment slightly
reduced the cell viability (80 ± 13% vs. 87 ± 11% of
mature DCs, p = 0.01, paired t-test; Figure 1B) and yield
of DCs (45 ± 17% vs. 70 ± 19%, p = 0.0071, paired t-test;
Figure 1C) (n = 5). Treatment with Dexa and Rapa did
not affect these outcomes (viability: 89 ± 6% and 90 ± 8%
and yield: 60 ± 23% and 83 ± 16%; respectively, n = 5).
Dexa-and Vit D3-tol-DC phenotypes change and produce
IL-10
The tolerogenic functions of DCs may depend on their
maturation stage and their anti-inflammatory profile.
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Page 3 of 14Thus, in our initial studies, we investigated the surface
phenotypes and cytokine milieus of tol-DCs obtained
using the 3 different immunomodulatory agents.
After 6 days of differentiation, immature DCs (Im-
DCs) expressed low surface levels of MHC II and co-sti-
mulatory molecules (CD86 and CD83; n = 15) as com-
pared with mature DCs (Mat-DCs) (Table 1 and Figures
2A and 2B). Tol-DC generation in the presence of Dexa
and VitD3 was associated with an immature phenotype
as compared to Mat-DCs. This phenotypic impairment
may affect the whole population or may be observed
as a partial maturation induced in a relatively low
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Figure 1 Survival of tol-DCs after clinical protocol differentiation. (A) Viability of MDDCs with or without immunomodulatory treatment
after 6 days of differentiation. Plots are representative of 5 independent experiments. (B) Surviving cells are annexin V and 7AAD negative cells.
(C) Yield obtained calculated as the number of MDDCs obtained from the initial number of monocytes that were cultured (n = 5). (paired t-test.
*p≤ 0.05; ** p ≤ 0.001; ***≤ 0.0001).
Table 1 Surface markers on tolerogenic DCs
CD86 CD83 HLA-DR n
Im-DC 15737 ± 7681 *** 1316 ± 673 *** 39405 ± 33712 ** 15
Mat-DC 22704 ± 13632 4371 ± 3189 70692 ± 66038 15
Dexa-DC 12291 ± 11364 *** 2811 ± 2343 * 50928 ± 62830 11
Rapa-DC 23782 ± 10961 4785 ± 2786 75297 ± 56014 15
VitD3-DC 6398 ± 6243 ** 1941 ± 3096 ** 20851 ± 38803 ** 11
Surface markers expression was measured by flow cytometry on MDDC.
Results are the averages ± SDs of Mean Fluorescence Intensity (MFI) from
different donors; n (number of samples). Mature DCs were used as a reference
group for all comparisons. * p ≤ 0,05; ** p ≤ 0,001; *** p ≤ 0,0001 (paired t-
test) indicating significant differences compared to MDDCs.
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Figure 2 Dexa-and VitD3-DCs exhibit a semi-mature phenotype as compared with Mat-DCs. (A) DC expression of maturation-associated
markers of immature DCs (Im-DCs), mature DCs (Mat-DCs) and tol-DCs. Surface expression of CD86-FITC, CD83-APC and HLA-DR-APCH7 staining
on MDDCs. Each histogram is representative of 15 independent experiments. Isotype controls are shown in grey. (B) Results are mean
fluorescence intensities from n = 11 cultures in the presence of Dexa, n = 15 cultures with Rapa-DCs and n = 11 cultures with VitD3-DCs. (paired
t-test. * p ≤ 0.05; ** p ≤ 0.001; ***≤ 0.0001).
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Page 5 of 14proportion of cells compared to the mature situation.
The latter was often observed in most cases of our results.
Indeed, in several experiments the percentage of cells with
low CD83 and HLA DR levels ("semi-mature”) was over
75%. As our study aimed for the comparison of the popu-
lations obtained under different tolerogenic regimes, we
considered that the analyses of the whole population
would better reflect these comparisons. VitD3-DCs
showed a significantly reduced expression of CD86, CD83
and HLA-DR (n = 11). Dexa-tol-DCs exhibited a similar
pattern, although only CD86 and CD83 showed signifi-
cantly reduced expression levels (n = 11). In contrast,
Rapa-tol-DCs were not phenotypically different from Mat-
DCs (n = 15) (Table 1 and Figures 2A and 2B).
In addition, we measured the secretion of IL-10 and
IL-12p70 after 48 h upon maturation. We found IL-10
production in cultures with either Dexa or VitD3, but
not with Rapa (Figure 3A). Of note, the production of
IL-10 in the presence of dexamethasone was 6 times
higher compared to mature DCs (1305 ± 846 pg/mL vs.
204.5 ± 160.5 pg/mL; p = 0.0135, n = 6, paired t-test).
Also, VitD3 tol-DCs produced slightly more IL-10 than
mature cells (243 ± 272.9 pg/mL vs. 204.5 ± 160.5 pg/
mL, n = 11). In contrast, IL-12 was notably undetectable
in all culture conditions (data not shown).
Stability of Tol-DCs after restimulation with LPS
To evaluate whether DCs were resistant to an exogen-
ous maturation stimulus, tol-DC stability was investi-
gated by culturing tol-DCs for 24 h in XVIVO medium
containing LPS (without immunomodulatory agent). As
shown in Figure 3B, tol-DCs were phenotypically refrac-
tory to secondary stimulation, and retained their typical
cytokine profile of IL-10 production. Dexa tol-DCs resti-
mulated with LPS produced 19 times more IL-10 than
Dexa-DCs (165.1 ± 203.7 pg/mL vs. 3244 ± 828.6 pg/
m L ,p=0 . 0 0 4 6 ,n=4 ,p a i r e dt - t e s t ) .R e g a r d i n gV i t D 3 -
DCs, LPS-restimulation did not greatly modified the IL-
10 production. Again, Rapa tol-DCs did not exhibit any
IL-10 production.
Importantly, while primary stimulation of the DCs
with this strong TLR4 ligand induced greater IL-23 pro-
duction by immature DCs (10.86 ± 6.5 fold increase), no
increased IL-23 production was detected by tol-DCs in
any culture condition (Dexa-DC: 1.11 ± 0.46; Rapa: 1.22
± 0.84; VitD3: 1.08 ± 0.51 fold changes), which sup-
ported a stable non-proinflamatory profile for tol-DCs.
Mat-DC also showed some refractoriness to the ulterior
stimulation with LPS, meaning there was a faint produc-
tion of cytokines “de novo” as opposite to Im-DCs.
DC-tols do not promote a Th1 profile
To analyze the effect of the different tol-DCs, allostimu-
lated T cells were further studied. An example of the
proliferation of T cells allostimulated by tol-DCs is
shown in Figure 4A. We have also summarized the rela-
tive results achieved using mature-DCs for different
donors in Figure 4B. Of mention, we found that Dexa-
DCs inhibited T cell proliferation only partially in some
donors (4/12 subjects, data not shown).
To further investigate the effect of tol-DCs on T cells,
we also determined whether inhibition of T cell prolifera-
tion was due to increased T cell apoptosis. We found that
the reduced stimulation of T cell proliferation was not due
to a reduction in cell viability induced by a particular type
of tol-DC (% of both Annexin V and 7AAD negative cells)
of allostimulated T cells (Im: 61.76 ± 9.28%; Mat: 65.92 ±
10.13%; Dexa: 62.08 ± 9.21%; Rapa: 61.02 ± 11.12% and
VitD3: 60.43 ± 11.72%; n = 4) (Figure 4C).
To gain some insight into the cytokines secreted by
these responding T cells, CFSE
low alloproliferative T
lymphocytes were re-stimulated with PMA + ionomycin
and IFN-g production was measured by intracellular
staining. These results confirmed a reduction of about
50-60% in IFN-g production relative to mature DCs for
all conditions tested (Figures 5A and 5B: 50.18 ± 16.65%
IFN-g producing cells among T cells allostimulated by
Dexa-DC, p = 0,0093, n = 4, paired t-test; 39.83 ±
16.76% Rapa-DC, p < 0,0001, n = 7, paired t-test; and
37.97 ± 44.08 VitD3-DC, p = 0,0098, n = 7, paired t-
test). When only CFSE
low proliferating T cells were ana-
lysed, Rapa-DCs stimulated T cells showed a significant
decrease in IFN-g production relative to Mat-DCs (Fig-
ure 5C: 40.99 ± 9.2% vs. 52.47 ± 10.85% IFN-g among
CFSE
low CD3+ cells, n = 7, p = 0,0057, paired t-test).
VitD3-DCs also suppressed IFN-g production in co-cul-
tures with allogeneic mononuclear cells, but only in
some donors and Dexa-DCs did not reduce the capabil-
ity of responding T cells to produce IFN-g in any of the
experiments.
In addition, we determined the production of IL-10
and TGFb in the supernatants from T cells co-cultured
with tol-DC. We could measure IL-10 production in
allostimulated T cells by Dexa-DC in 3 of 4 donors.
Interleukin 10 values obtained were 57.47 ± 29.47 pg/
mL (T cells + Dexa-DCs) compared to 33.37 ± 2.66 pg/
mL (T cells allostimulated with Mat-DCs). Conversely,
we did not find major differences in T cells stimulated
with Rapa-DC (15.7 ± 13.61 pg/mL) or VitD3-DC (38.7
± 7.28 pg/mL) compared to mature DCs (n = 3).
Regarding TGFb,a l lt h em e a s u r e sw e r eb e l o wt h el i m i t
of detection of the assay (60 pg/mL) in the different sti-
mulatory conditions analyzed.
Finally, the presence of Tregs cells defined as CD4+
CD127 low/negative CD25high and Foxp3+ as reported
before (72) was estimated in these culture conditions.
After one round of stimulation for 6 days, we analysed the
induction of CD4+ Foxp3+ and CD25
high, CD127
low/negative
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those T cells stimulated by Rapa-DCs showed a signifi-
cantly increase of the percentages of CD4+ Foxp3+ and
CD25
high, CD127
low/negative cells (5.4 ± 1.9% vs. 3.5 ±
1.7% with Mat-DCs, p = 0.0211, n = 6, paired t test)
(Figure 6B).
Discussion
Induction of therapeutic tolerance is of increasing inter-
est in autoimmunity, allograft rejection, allergy, asthma,
and various forms of hypersensitivity. Because of their
capacity to orchestrate immune responses, DCs can be
used as therapeutic agents. The classical concept that
A
B
Figure 3 Tolerogenic dendritic cells (tol-DCs) exhibit an anti-inflammatory cytokine profile and stable phenotype. (A) IL-10 release by
DCs in the presence or absence of immunomodulatory agents (Dexa, Rapa or VitD3) was measured after 48 h stimulation with a maturation
cocktail. Supernatants were harvested and analysed for IL-10 production by MILLIPLEX (Dexa: n = 6; Rapa: n = 7 and VitD3: n = 11). (B) Stability
of tol-DCs was evaluated after culture for 24 h in XVIVO medium containing LPS (without immunomodulatory agent). IL-10 and IL-23 production
was determined for all DC conditions (with or without LPS). (n = 4. Statistical significance derived from a paired t-test. * p ≤ 0.05).
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Page 7 of 14immature DCs induce tolerance and that mature DCs
induce immune responses has changed completely, and
several lines of evidence demonstrate that the maturation
state of DCs does not always correlate with their toleris-
ing or activating functions [43]. In this sense, the
definition of tol-DCs must include a maturation-resistant
cell that acts as “an immature DC” with a stable pheno-
type that is preserved, even in the presence of pro-inflam-
matory signals. This tolerogenic state of DCs can be
induced using several pharmacological agents [44-46].
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Figure 4 Tolerogenic dendritic cells (tol-DCs) suppress T cell proliferation without apoptosis induction. (A and B) Allogeneic T cells were
stimulated with tol-DCs and compared for proliferation with stimulation by Mat-DCs and Im-DCs in mixed-lymphocyte reactions. Compared to
Mat-DCs, tol-DCs potently inhibited allogeneic T cell proliferation at a level similar to Im-DCs (Dexa: n = 7; Rapa: n = 10; and Vit D3: n = 10). (C)
Viability results (%Annexin V and 7AAD negative) for T cells co-cultured with different cellular products (n = 4).
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Figure 5 Decreased production and secretion of IFN-g by T lymphocytes stimulated with tol-DCs. Proliferating T lymphocytes were
obtained from allostimulatory cultures. The production of interferon (IFN)-g was measured by intracellular staining after restimulating the cells
with PMA+Io in the presence of brefeldin for 5 h. (A) First row (i) shows gating CD3+ cells. The second row plots (ii) indicate the proportion of
total IFN-g producing cells. Third row (iii) shows the percentages of cells that responded to allostimulation (CFSElow) and produced IFN-g. The
numbers inside the plots indicate the percentage of cells in each quadrant or boxes (a representative experiment). (B) Summary of the results of
the total intracellular IFN-g (Upper Left, UL) production with Dexa-(n = 4), Rapa-(n = 7) and Vit D3 (n = 7) activated cultures relative to Mat-DCs
(taken as 100% production). (C) Percentage of IFN-g producing T cells that responded to allostimulation (CFSE
low CD3+ cells). Each symbol
represents an individual sample. Significant differences are indicated (** p < 0,001; paired t-test).
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Figure 6 Rapa-DCs promote CD4+CD25
hiCD127
lowFoxP3+ induction from blast T cells. After 6 days of culture without re-stimulation and
any supplemental cytokines, cell sizes were evaluated by FACS by plotting forward scatter (FSC) versus side scatter (SSC) parameters. Small (solid
line) non-blast cells and large (dotted line) blast cells are circled. (A) Phenotype of T cells as CD4+, Foxp3+ and CD25+ with low or null CD127
expression. One of 6 representative experiments is shown. (B) Summary of percentages of T cells in non-blast (left) and blast (right) cells. (* p ≤
0.05, n = 6, paired t-test).
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Page 10 of 14At present, scattered knowledge from different tolero-
genic cellular products can be found. A better under-
standing of clinical grade cellular therapies may offer
new opportunities for treating different disorders. How-
ever, several gaps in our knowledge remain to be filled-
i nb e f o r eap e r f e c tt o l e r o g e n i cD C( o n eb e s ts u i t e df o r
targeting a particular process) may be envisaged. Thus,
our work aimed to determine the capabilities of those
GMP-grade immunosuppressive drugs (dexamethasone,
rapamycin and vitamin D3) that are used to obtain tol-
DCs in comparative scenarios and identify the “array” of
their individual characteristics, such as phenotypes, cyto-
kine profiles, resistance to maturation, and T-cell pro-
files, in order to define the best DCs for a particular
situation.
Hence, we report for the first time a comparative
study of clinical-grade tolerogenic cellular products for
therapeutic applications that fulfil the regulatory medical
rules for human therapy. Our results show that all clini-
cal-grade tol-DCs that were analysed function as “nega-
tive cellular vaccines,” which are comparable to
previously characterised research-grade tol-DCs [47]. In
terms of viability, we observed that VitD3 had a slight
tendency to promote DC apoptosis, in accordance with
previous reports [48]. However, this minor reduction in
cell viability does not compromise either DC functional-
ity or the eventual use of these cells in therapy.
Although apoptosis induction in DCs by pharmacologi-
cal agents has been controversial, several reports
demonstrated that Dexa did not induce cell death in
MDDCs at any of the tested concentrations [49,50].
Also, use of Rapa for DC maturation did not increase
apoptosis [51], in agreement with our results.
When analysing the phenotypes of the generated tol-
DCs, we observed that only Dexa-and VitD3-DCs had
reduced classical markers of mature cells on their sur-
faces. However, Rapa-DCs did not show an immature
phenotype, thus being characterized as “mature DCs”
with respect to their exhibited phenotype. In this con-
text, it is obvious that the definition of DC maturation
using phenotype markers is not a distinguishing feature
of immunogenicity nor tolerogenicity [40]. Thus, a set
of “biomarkers” for tolerance induction in our cellular
products have to be defined to better monitor the puta-
tive tolerogenic cells [17,37], as phenotypic identification
of tol-DCs may not be as accurate as expected. Ideally,
quality controls for tol-DCs should be based on markers
that are quickly and readily detectable and that are
reliable.
From the cytokine profile results, Dexa-and moder-
ately VitD3-derived DCs showed increased IL-10 pro-
duction, whereas the secretion of IL-12p70 was not
detected in all cases. It is well known that IL-10 blocks
IL-12 synthesis by DCs, downregulates the expression of
co-stimulatory molecules and potentiates their tolero-
genicity [43,52]. This tolerogenic feature was not
observed with Rapa-DCs, as was previously reported
[53]. Most likely, DCs modified by Rapa use some other
mechanism to induce tolerance, as discussed below.
Resistance to maturation is considered a prerequisite
of tolerogenic potential for ‘’negative cellular vaccines’’.
Under the influence of inflammation, the administered
immature DCs should potentially undergo maturation
and lose their tolerogenic function. Thus, for good clini-
cal applications, tol-DCs should show a stable immuno-
suppressive phenotype that will not be transformed to
immunostimulatory DCs after injection into patients. In
this context, several methods have been described for
designing maturation-resistant DCs [54-57]. Our results
show that Dexa-DCs, and to a lesser extent VitD3-DCs,
exhibit a durable “immaturity,” as high IL-10 production
and no IL-12/IL-23 production was maintained upon
subsequent TLR stimulation. In agreement with this,
Xia et al. previously demonstrated that this tolerogenic
product preserves this feature up to 5 days after remov-
ing Dexa [58]. As described in the literature, immature
DCs undergo maturation and lose their tolerogenic
functions. Interestingly, the cytokine profiles of the gen-
erated tol-DCs were not modified by a strong TLR sti-
mulation, indicating that they maintained a stable
profile.
Another functional property of tol-DCs is their
decreased T cell-stimulatory capability. We further
investigated the immunoregulatory capability of clinical-
grade tol-DCs using direct T cell activation in mixed-
lymphocyte reactions. Our results showed differential
potentials for reducing proliferation: Rapa and VitD3
worked in the nM range, while Dexa required higher
concentrations in the μM range. In fact, tolerogenic
MDDCs conditioned with Dexa from 1/3 of the indivi-
duals (4/12) did not acquire regulatory properties at the
concentration used, and even showed a “semi-mature”
phenotype. In this regard, the possibility of combining
Dexa with VitD3 to prevent de-sensitization of the DCs
to the actions of Dexa has been reported [11]. Further-
more, both immunomodulatory agents used in combina-
tion inhibit DC maturation and function in an additive
manner [7,59,60].
In addition, total IFN-g production was significantly
reduced when these T cells were stimulated by tol-DCs.
To extend our analyses, we evaluated IFN-g in T cells
that had responded to allostimulation and observed that
IFN-g production was only reduced when Rapa-DCs
were used as stimulators. This property in the deviation
of Th differentiation was also observed previously by
Monti P. et al [61].
It has been described that tolerogenic DCs induce
immune tolerance through several pathways, including
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of Th differentiation or generation of Tregs [15,62-68].
To deduce which mechanisms that tol-DCs might have
exerted, the possibility of apoptosis induction was evalu-
ated. However, we did not find any differences in cell
death by allostimulated T cells, indicating that this
mechanism was not acting in our cellular products. In
contrast, it has been reported that Dexa-and VitD3-DCs
induced a hyporesponsiveness as a strategy to dampen
autoreactive responses [50], and our own observations
(Raïch-Regué D. et al) support these results.
Finally, we tested for the induction of CD4+CD25
hiC-
D127
lowFoxP3+ T cells. Regulatory T cells suppress the
responses of alloreactive or self-reactive CD4+ T cells
and are supposed to maintain immunologic self-toler-
ance or control autoimmunity [69-71]. Rapa-DC-primed
T cells exhibited reduced alloproliferation along with a
concomitant expansion of CD4+CD25
hiCD127
lowFoxP3+
cells [72-74]. This effect may have been in response to
the expression of high levels of CD86 and is consistent
with previous reports that described that co-stimulation
is required for induction and expansion of FoxP3+
Tregs [53,75,76]. In contrast, Dexa and VitD3 did not
induce this phenotype on T cells. This discrepancy with
the literature could be due to the particular experimen-
tal approaches. It is important to note that we analyzed
these T cells in co-cultures of MDDCs with allogenic T
cells for one round of stimulation. However, it has been
demonstrated that VitD3-DCs convert naive T cells into
Tregs after several rounds of priming and boosting [77].
Another possibility to explore was the presence of other
CD4+ Treg subsets, including CD4+CD25-FoxP3-IL-10
producing Tr1 cells [78,79] and transforming growth
factor-b (TGF-b+) Th3 cells [80]. In this sense, our
results show IL-10 production on T cells stimulated by
Dexa-DCs but not TGF-b in any of cultured conditions.
Conclusions
In summary, in these comparative analyses of clinical
grade tol-DCs, Dexa-and VitD3-DCs exhibited a “semi-
immature” phenotype and IL-10 secretion. In contrast,
Rapa-DCs induced CD4+CD25
hiCD127
lowFoxP3+ and
inhibited IFN-g secretion by allostimulated T cells. This
comparative study emphasises the fact that a simple
phenotypic determination of maturation markers does
not guarantee a tolerogenic function and that a com-
plete set of functional determinations is mandatory in
order to clearly define a tolerogenic “functional” pheno-
type. This also stresses the necessity to define reliable
biomarkers for applications in GMP labs. Finally, this
may also help with decisions on which tolerogenic pro-
duct will be the best for a particular situation. Phase I-II
studies with quality control measures and appropriate
clinical and immunological outcomes must be per-
formed to evaluate potential tol-DC functions.
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